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Newcastle-Upon-Tyne NE2 4HH, UKSummary holic liver disease (ALD), non-alcoholic fatty liver diseaseS-adenosyl-L-methionine (SAMe; AdoMet) is an important, meta-
bolically pleiotropic molecule that participates in multiple cellu-
lar reactions as the precursor for the synthesis of glutathione and
principle methyl donor required for methylation of nucleic acids,
phospholipids, histones, biogenic amines, and proteins. SAMe
synthesis is depressed in chronic liver disease and so there has
been considerable interest in the utility of SAMe to ameliorate
disease severity. Despite encouraging pre-clinical data conﬁrm-
ing that SAMe depletion can exacerbate liver injury and support-
ing a hepatoprotective role for SAMe therapy, to date no large,
high-quality randomised clinical trials have been performed that
establish clinical utility in speciﬁc disease states. Here, we offer
an in-depth review of the published scientiﬁc literature relating
to the physiological and pathophysiological roles of SAMe and
its therapeutic use in liver disease, critically assessing implica-
tions for clinical practice and offering recommendations for fur-
ther research.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The need for therapies to ameliorate liver injury
Liver disease is considered acute or chronic according to the
duration of the injurious process. The process of hepatic ﬁbrogen-
esis is triggered by tissue damage and continues until the lesion
is healed. If the damage persists or is recurrent, the repair process
will persist and ﬁbrogenesis will progress towards cirrhosis, liver
failure or hepatocellular carcinoma [1,2]. Hepatocyte death,
through a varying combination of oncotic necrosis and apoptosis,
is a characteristic feature of most liver diseases including alco-Journal of Hepatology 20
Keywords: S-adenosyl-L-methionine; SAMe; Hepatitis; Steatohepatitis; Oxidative
stress.
Received 19 March 2012; received in revised form 12 April 2012; accepted 15 April
2012
⇑ Corresponding author. Address: Institute of Cellular Medicine, The Medical
School, Newcastle University, 3rd Floor, William Leech Building, Framlington
Place, Newcastle-upon-Tyne NE2 4HH, UK. Tel.: +44 (0) 191 222 7012; fax: +44
(0) 191 222 0723.
E-mail address: quentin.anstee@newcastle.ac.uk (Q.M. Anstee).(NAFLD), cholestasis, viral hepatitis, ischemia/reperfusion, liver
preservation at transplantation and drug/toxin-induced injury
[3]. Correction of the underlying aetiology before the develop-
ment of cirrhosis and liver failure is the primary goal in managing
liver disease. However, where this is not possible, treatment to
ameliorate hepatocellular injury or control ﬁbrogenesis offers
an attractive therapeutic strategy that may prevent disease pro-
gression and, given that ﬁbrosis has a reversible component,
allow regression [4,5]. At present, there are no accepted anti-
ﬁbrotic agents available outside clinical trials and, beyond the
use of N-acetylcysteine (NAc) in the treatment of acute acetami-
nophen (paracetamol) toxicity, there are no widely adopted
agents that limit hepatocellular injury in routine clinical use.
Irrespective of aetiology, progression of liver disease is inﬂu-
enced by the interaction of host genetic factors, the pathogen,
and other coincidental environmental inﬂuences [6]. Nutritional
status is one such factor [7]. However, it has also become appar-
ent that beyond dietary availability of speciﬁc nutrients and
essential amino acids, an individual’s metabolic capacity for pro-
cessing them into active metabolites and the factors that inﬂu-
ence this can profoundly affect physiology in health and disease
[8]. The essential amino acid methionine and its biologically
active metabolite S-adenosyl-L-methionine (SAMe; AdoMet) are
a case in point: there is evidence that SAMe depletion occurs dur-
ing chronic liver disease [9,10] and SAMe has been proposed as
treatment for certain disease states [8,11]. Due to encouraging
data from early studies and the lack of other effective agents,
SAMe has been widely adopted in Eastern Europe, Russia, China,
Southern Asia, and South America as a therapy for chronic liver
disease and intra-hepatic cholestasis. It is therefore timely to dis-
cuss the role of SAMe in the pathogenesis of liver disease and crit-
ically review the current evidence of clinical utility for SAMe
supplementation.S-adenosyl-L-methionine (SAMe)
Hepatic SAMe metabolism
SAMe is synthesised from dietary L-methionine and ATP by the
enzyme methionine adenosyltransferase (MAT; EC 2.5.1.6) in a
complex two-step reaction [12,13]. The complete tripolyphos-
phate (PPPi) moiety is cleaved from ATP at the C-50 atom and
the adenosyl moiety is transferred to methionine to form SAMe;12 vol. 57 j 1097–1109
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PPPi is then hydrolysed to orthophosphate and pyrophosphate
(PPi + Pi) at a distinct sub-site within the MAT catalytic domain;
and ﬁnally SAMe, orthophosphate and pyrophosphate are
released (Fig. 1) [9]. In mammals, there are three separate forms
of the MAT enzyme [14]. The gene MAT1A is predominantly
expressed in the adult liver and encodes a 395 amino acid a1 cat-
alytic subunit that is combined into either a homotetramer
(MATI) or a homodimer (MATIII) [15]. In contrast, MAT2A is ubiq-
uitously expressed in all mammalian tissues studied including
foetal liver (and to a lesser extent in adult liver), erythrocytes,
lymphocytes, brain and kidney [15–17]. It encodes a 396 amino
acid a2 catalytic subunit that combines with a non-catalytic
334 amino acid regulatory b subunit encoded by MAT2B to formMethio
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Fig. 1. Metabolic pathways in methionine/SAMe metabolism. SAMe is synthesised fro
(MAT; 1). In standard conditions, the majority of SAMe generated is used in transmeth
methyltransferase in the liver. Irrespective of the speciﬁc enzyme mediating the rea
conversion into homocysteine and adenosine in a reversible reaction catalysed by
remethylation pathways or the transsulfuration pathways. In the former, homocysteine
(MS; 4) or betaine methyltransferase (BHMT; 5) to re-form methionine. Alternatively
(CBS; 6) begins the transsulfuration pathway leading to cysteine and ultimately gluta
required for functioning of MS (4), CBS (6) and BHMT (5), respectively. Modiﬁed from
1098 Journal of Hepatology 2012the MATII isoform of the enzyme [12,15,16]. MAT is a highly con-
served enzyme throughout evolution with a 59% sequence
homology between Escherichia coli and humans [9]. Both the a1
and a2 subunits share approximately 84% amino acid sequence
homology [15] however, the MATII a2/b dimer has lower sub-
strate afﬁnity (km) than MATI/III and its activity is negatively reg-
ulated by SAMe as intracellular concentration increases whilst
MATI/III is not. These differences in regulatory and kinetic prop-
erties limit MATII activity, which is thought to contribute little to
hepatic methionine metabolism in healthy adults under normal
physiological conditions whilst the MAT1A coded isoforms
(MATI/III) maintain high levels of SAMe synthesis (approximately
6–8 g/day) [12].nine  
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Regulation of MAT expression and SAMe synthesis
Synthesis of SAMe needs signiﬁcant metabolic energy given the
requirement to hydrolyse the three high-energy phosphodiester
bonds of ATP for each SAMe molecule synthesised. To control
these demands, MATI/III activity is regulated both at transcrip-
tion level and through post-translational regulation. Sequencing
the MAT1A promoter region has identiﬁed consensus binding
sites for several transcription factors including C/EBP (CAAT
enhancer binding protein), NF-1 (nuclear factor 1), and HNF
(hepatocyte-enriched nuclear factor) [12]. However, studies have
demonstrated that, although MAT1A expression is limited to the
liver, promoter activity is present in cells from other tissues
and so this is unlikely to be the mechanism through which tissue
speciﬁc expression is mediated. Beyond promoter activity, gene
transcription may be controlled by DNA methylation that can
directly impede binding of transcription proteins and can addi-
tionally inﬂuence histone deacetylation and therefore chromatin
structure. Hypermethylation of two MAT1A promoter CpG sites
has been demonstrated in foetal liver, hepatocellular carcinoma
(HCC) and extra-hepatic tissues, whilst these sites were found
to be demethylated in normal adult liver where the gene is
expressed [18]. Further, the degree of histone acetylation, neces-
sary to maintain chromatin in a decondensed and active state for
transcription, is modiﬁed so that the degree of H4 histone acety-
lation associated with the MAT1A promoter is approximately 15-
fold greater in the liver than in tissues where MAT1A is not
expressed such as the kidney [18]. In human hepatoma cell lines
(e.g. HepG2), MAT1A is hypermethylated and so not expressed,
while exposure of these cells to the demethylating agent 50-
aza-2-deoxycytidine or to the histone deacetylase inhibitor tri-
costatin A promotes gene expression [9,18]. Together, these ﬁnd-
ings indicate that tissue-speciﬁc MATI/III expression is primarily
regulated through DNA methylation and histone deacetylation
and that this may be affected by disease states (Fig. 2).
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methylation and histone deacetylation and this may be affected by disease states. Great
where MAT1A expression is suppressed and less MATI/III activity observed. Modiﬁed fro
Journal of Hepatology 2012there is an additional need to rapidly ‘ﬁne tune’ SAMe synthesis
according to variations in metabolic demand to prevent hepato-
cytes becoming ATP depleted at times of metabolic stress [12].
Reactive oxygen species (ROS) and nitric oxide (NO) can inacti-
vate MATI/III by oxidation or S-nitrosylation of the cysteine resi-
due at position 121 in the a1 subunit, respectively, inducing a
conformational change in the protein that blocks the catalytic
site. This change can be equally rapidly reversed by exposure to
physiological concentrations of the anti-oxidant glutathione,
reactivating MATI/III [19–21]. Importantly, MATII does not pos-
sess a cysteine residue at the equivalent position and so its activ-
ity (which is regulated by SAMe concentration) is not inﬂuenced
by oxidative stress. Indeed, inhibition of MATI/III under condi-
tions of oxidative stress causes SAMe levels to fall, disinhibiting
MATII.
Physiological role of SAMe
SAMe is an important, metabolically pleiotropic molecule that
participates in multiple cellular reactions and inﬂuences numer-
ous cellular functions. Biochemically, it participates in three
types of reaction: transmethylation, transsulfuration and amino-
propylation [22,23]. A comprehensive discussion of these meta-
bolic pathways falls outside the scope of this review however,
the key reactions will be brieﬂy summarised.
SAMe is the principle methyl donor required for methylation
of nucleic acids, phospholipids, histones, biogenic amines, and
proteins [23]. In standard conditions, the majority of SAMe gen-
erated is used in transmethylation reactions (Fig. 1). Glycine-N-
methyl transferase (GNMT; EC 2.1.1.20) is the most abundant
methyltransferase in the liver and is also present in the exocrine
pancreas and prostate. Irrespective of the speciﬁc enzyme medi-
ating the reaction, a common product is S-adenosylhomocysteine
(SAH). Clearance of SAH by conversion into homocysteine and
adenosine in a reversible reaction catalysed by SAH hydrolase
(EC 3.3.1.1) is essential as many SAMe-dependent methylation
reactions are strongly inhibited by SAH accumulation.ionnally 
ible
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Homocysteine lies at the intersection of the remethylation
pathway and the transsulfuration pathway through which homo-
cysteine may be processed to form the primary endogenous cel-
lular antioxidant, glutathione (Fig. 1) [10]. In the former,
homocysteine is remethylated by methionine synthase (MS; EC
2.1.1.13) in a process coupled to the folate cycle or betaine meth-
yltransferase (BHMT; EC 2.1.1.5) to re-formmethionine; although
it should be noted that the role of BHMT is of much less signiﬁ-
cance in primates than in rodents [23]. Alternatively, the conver-
sion of homocysteine to crystathionine by crystathionine b-
synthase (CBS; EC 4.2.1.22) begins the transsulfuration pathway
through which the methionine derived sulphur atom in SAMe
is processed stepwise into cysteine and ultimately glutathione
(Fig. 1). These pathways are autoregulated by hepatic SAMe con-
centration which acts as a potent inhibitor of MS and BHMT
activity and an activator of CBS so that excess SAMe is preferen-
tially partitioned into glutathione [24]. Folic acid, and the co-fac-
tors vitamin B6 and B12 are required for functioning of MS, CBS,
and BHMT, respectively, and so their availability will limit enzy-
matic activity and thus homocysteine levels and hepatic methio-
nine handling (Fig. 1) [10]. SAMe is also the precursor for the
synthesis of polyamines that are needed to preserve cell viability
and proliferation. Here, SAMe is decarboxylated by SAMe decar-
boxylase (EC 4.1.1.50) and the aminopropyl group used to from
polyamines including the biologically active metabolite 5’-meth-
ylthioadenosine (MTA).
SAMe metabolism in liver disease
Recognition that methionine metabolism is impaired in patients
with chronic liver disease extends back more than 60 years to
studies demonstrating reduced methionine clearance after liver
injury [25]. Independent of aetiology, patients with hepatic cir-
rhosis have been shown to have reduced MAT1A expression,
lower MATI/III activity, with no compensatory increase in MAT2A
expression and therefore hepatocellular accumulation of methio-
nine and signiﬁcantly reduced levels of SAMe [26,27]. These
changes are due to hypermethylation of the MAT1A promoter
limiting gene expression in cirrhotic patients, however, the
mechanism through which this occurs is not known (Fig. 2)
[27]. Furthermore, conditions that promote oxidative stress such
as alcohol consumption, viral hepatitis, septic shock, and toxin
exposure; or increase nitric oxide (NO) synthesis such as hypoxia
and inﬂammatory cytokines (e.g. TNFa, IL-6) will inactivate resid-
ual MATI/III [12]. Given that SAMe is a biochemical intermediary
in glutathione synthesis, this in turn will further downgrade
hepatocellular defences against oxidative stress and worsen liver
injury.
The effects of chronic SAMe depletion may be studied in the
Mat1a null (MATO) mice [28]. In these mice, hepatic hyperplasia
is evident by 3 months of age; young animals are more sensitive
to choline-deﬁcient diet induced steatosis; and, consistent with
the effects of methionine/choline-deﬁcient dietary models [29],
the mice develop spontaneous steatohepatitis by age 8 months
[28]. Gene expression proﬁling reveals that, even when the liver
appears histologically normal, numerous growth, dedifferentia-
tion and acute phase response genes are upregulated including
proliferating cell nuclear antigen, a-fetoprotein, and Mat2a.
MATO mice are also signiﬁcantly more sensitive to the effects
of carbon tetrachloride exposure than wild type animals, exhibit-
ing higher levels of ALT, AST, and greater histological liver injury1100 Journal of Hepatology 2012[12]. Few human examples of spontaneous MAT1A deﬁciency
have been reported, however, it is notable that neurological
rather than hepatic dysfunction is the primary phenotype
described (OMIM #610550).
Beyond its role as a metabolic intermediate, there is evidence
that the balance between MATI/III and MATII activation and
therefore intracellular SAMe concentration can modulate cell
proliferation in the liver. SAMe levels are high in quiescent hepa-
tocytes but are much lower in proliferating cells [30]. Studies in
HepG2 and HuH7 cells demonstrate that when MAT2A is
expressed, low SAMe levels promote more rapid cell growth
whilst increased SAMe synthesis due to MAT1A expression or
SAMe treatment is associated with slower growth [30]. These
ﬁndings are also supported by reports that the potent mitogen,
hepatocyte growth factor (HGF), induces acetylation of histones
associated with the MAT2A promoter, an effect that can be over-
come by administration of exogenous SAMe [31,32]. In vivo, fol-
lowing partial hepatectomy in the rat, SAMe levels are
markedly reduced, coinciding with the start of DNA synthesis
and regeneration. Once again, hepatocellular regeneration can
be inhibited by SAMe administration [33]. Underlining the clini-
cal signiﬁcance of the effect of SAMe on hepatocellular prolifera-
tion, SAMe depletion in Mat1a knockout mice is associated with
spontaneous development of HCC [34,35] whilst development
of HCC in carcinogen-exposed rats can be blocked by SAMe treat-
ment [36,37]. Thus, SAMe depletion promotes increased cellular
proliferation and growth. As a short lived response to an acute
insult these changes may be beneﬁcial: SAMe synthesis is reset
to a new lower steady state preserving ATP, hepatocyte prolifer-
ation and growth are prioritised and the original liver mass
restored. However, if injury becomes chronic, SAMe depletion
may be deleterious as it favours malignant transformation and
so SAMe supplementation, at least to physiological levels, may
be beneﬁcial.
Role of SAMe in modifying response to injury
Given our current understanding of methionine metabolism and
the physiological role of SAMe, it has been proposed that supple-
mentation could both ameliorate liver injury and reduce the
development of HCC in chronic liver disease. These effects cannot
be achieved by giving methionine, even a 7-fold increase in
methionine consumption was unable to signiﬁcantly increase
hepatic SAMe and could exacerbate the potentially harmful accu-
mulation of methionine that is observed in cirrhotic patients
[38,39]. Administration of SAMe would, however, bypass MAT
and theoretically avoid these problems. Before considering the
evidence for speciﬁc disease states, we will examine the role of
SAMe in hepatic pathophysiology and how this may be manipu-
lated through therapeutic supplementation.
Oxidative stress and cellular damage
A common feature in the pathophysiology of most inﬂammatory
processes is the involvement of reactive oxygen species (ROS)
such as superoxide, peroxynitrite, hydrogen peroxide, and the
hydroxyl radical [40]. Due to their high metabolic activity, ROS
are generated continuously in hepatocytes and also, following
liver injury, by cells of the innate immune system (e.g. Kupffer
cells, inﬁltrating monocytes/macrophages, and neutrophils).
These highly reactive chemical species react with cell membranes
causing lipid peroxidation, induce DNA damage, activate c-jun-N-vol. 57 j 1097–1109
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terminal kinase (JNK) and caspase signalling to promote apopto-
sis and cause oncotic necrosis [40]. To counter this, intracellular
ROS generation is largely conﬁned to speciﬁc organelles including
mitochondria and peroxisomes; several anti-oxidant enzyme sys-
tems have developed including superoxide dismutase (SOD), glu-
tathione peroxidise, and catalase that detoxify ROS; and cells
contain endogenous anti-oxidants which scavenge free radicals
to mitigate against cellular damage, the most abundant of which
is glutathione [41]. As discussed above, SAMe is a precursor for
the synthesis of cysteine and thus glutathione (Fig. 1) [12]. SAMe
has been shown to effectively increase intracellular glutathione
concentration in murine models [42–45] and in patients with
liver disease [46]. Importantly, SAMe can replenish hepatic mito-
chondrial glutathione and normalise ﬂuidity of the inner mito-
chondrial membrane, which is critical for maintenance of
function [43,45]. It is tempting to speculate that these effects
could underlie a reported amelioration of biochemical markers
of chemotherapy-related liver injury described in three retro-
spective, observational studies from Italy, however, hepatic glu-
tathione levels were not measured and so it would require
further, prospective assessment to conﬁrm these ﬁndings and
determine mechanism of action [47–49].
There is evidence that, beyond its effect on hepatocellular
ROS, SAMe may have additional beneﬁcial effects modulating
the balance between pro- and anti-inﬂammatory cytokines in
liver injury [11]. Experimental evidence of the ability of SAMe
to attenuate pro-inﬂammatory TNFa-mediated liver injury, likely
through downregulation of transcription factor NFjB, comes
from a number of studies [11,50]. Elevated glutathione levels
may also help reduce TNFa-induced necrosis [44]. In rats fed a
methionine–choline deﬁcient diet to induce steatohepatitis,
SAMe was shown to reduce the induction of TNFa expression
caused by exposure to bacterial lipopolysaccharide (LPS) [51].
Both SAMe and its metabolite from the polyamine pathway,
MTA, have also been shown to reduce TNFa production in vivo
and in vitro following LPS stimulation of the murine monocyte
cell line RAW264.7 [52,53], and to induce anti-inﬂammatory IL-
10 production in the same models [52–54].Apoptosis
The interactions between SAMe and apoptotic cell death path-
ways are complex. SAMe has been shown to inhibit bile acid-
induced apoptosis in vitro [55,56] and both SAMe and MTA
can protect normal cultured rat hepatocytes against okadaic
acid-induced apoptosis in a dose dependent manner, an effect
thought to be mediated through reduced mitochondrial cyto-
chrome-c release, caspase-3 activation, and poly(ADP-ribose)
polymerase cleavage [11,57]. However, SAMe has the opposite
effect on cancer cells [58]. For example, SAMe induces apopto-
sis in HepG2 and HuH7 cell lines via the mitochondrial death
pathway [58]. The reasons for the differential effect remain
incompletely understood but two mechanisms have been
proposed [10]. Firstly, SAMe and MTA alter cellular phosphory-
lation state and alternative splicing of genes in cancer cells
resulting in Bcl-xs induction and apoptosis; and secondly, SAMe
and MTA have been shown to directly inhibit BHMT activity in
cancer cells but not normal hepatocytes, perturbing homocyste-
ine metabolism, and promoting endoplasmic reticulum stress
and therefore apoptosis [10]. These effects are consistent with
the observed in vivo chemopreventive effects of SAMe in
murine models of HCC where more apoptotic bodies were seenJournal of Hepatology 2012in tumours of SAMe-treated animals than in untreated controls
[36,37].
Transmethylation reactions and intra-hepatic cholestasis
Cholestasis occurs in a number of disease states and results in an
accumulation of potentially toxic bile salts in the liver and blood
which in turn leads to oxidative stress, hepatocellular injury, bile
duct proliferation, and ultimately hepatic ﬁbrosis [41,59]. Meth-
ylation status is recognised to be of fundamental importance to
cell membrane function with phospholipid methylation inﬂuenc-
ing membrane ﬂuidity and transport of metabolites and trans-
mission of signals across membranes [60–62]. As a major
methyl donor, availability of SAMe potentially has profound
effects on these processes. Therefore, it has been suggested that
SAMe depletion contributes to the development of intra-hepatic
cholestasis by interfering with bile salt export pump (BSEP) activ-
ity [8]. Furthermore, hepatocellular injury in cholestasis is fre-
quently associated with glutathione depletion and so SAMe
may help correct this [41].SAMe therapy for chronic liver disease
Intra-hepatic cholestasis
The efﬁcacy of SAMe therapy has been examined in a range of
chronic liver conditions, although historically the greatest inter-
est has been in the area of intra-hepatic cholestasis (IHC). IHC
is a syndrome that develops from impaired bile ﬂow at the
sub-lobular level. This may occur due to: (1) hepatocellular dam-
age, including viral hepatitis, alcoholic hepatitis or prolonged TPN
use; (2) canalicular membrane changes, often seen in drug-
induced liver injury (e.g. oral contraceptives, antibiotics, etc.);
(3) genetic defects in bile transporters; (4) obstruction of the can-
aliculi or ductules; and (5) ductopenia [63]. Clinically, IHC is char-
acterised by the presence of pruritus or jaundice with elevated
serum total bilirubin, alkaline phosphatise, and gamma-glutam-
yltransferase levels [63].
Pre-clinical and clinical therapeutic evidence in non-pregnancy
related cholestasis
The effects of SAMe treatment in vivo in rat models of surgical
cholestasis (bile duct ligation) have shown some beneﬁt. Rats
treated with SAMe and then subjected to bile duct ligation for
7 days were found to exhibit less oxidative stress as measured
by thiobarbituric acid reactive substances (TBARS) and to have
a reduced ratio of oxidised to total glutathione [64]. Perhaps
unsurprisingly, given the nature of the model, both this and a
similar study failed to detect any change in biochemical cholesta-
sis (ALT, ALP, and bilirubin), area of hepatocellular necrosis or
ﬁbrosis [41,64,65].
The two largest studies that have examined the utility of
SAMe therapy in this setting have both been conducted in
patients with features of IHC due to a mixture of different aetiol-
ogies [66,67]. One of the earliest was a multi-centre, double-blind
placebo-controlled trial conducted in 220 IHC patients, many of
indeterminate aetiology and of differing disease stage (68% cir-
rhosis, 26% chronic viral hepatitis, 6% PBC) [67]. This demon-
strated a signiﬁcant reduction in clinical biochemical indices of
cholestasis and improvement in symptoms of fatigue and pruri-
tus after oral SAMe treatment (1600 mg/day). This study alsovol. 57 j 1097–1109 1101
Table 1. Selected clinical trials of SAMe in non-pregnancy related IHC.
Study, [Ref.] Design Subjects (n) SAMe dose (g/day) Duration Outcome
*Frezza et al., 1990 [67] RCT 220 1600 mg/d po vs. 
placebo
2 wk RR Pruritus 0.43 (95% CI 0.27-0.69)
*Frezza et al., 1987 RCT 80 800 mg/d iv vs. 
placebo
2 wk RR Pruritus 0.00 (95% CI 0.25-0.53)
*Manzillo et al., 1992 [68] RCT 256 (pruritus studied in 
105 patient subgroup)
800 mg/d iv vs. 
placebo
2 wk Improved serum bilirubin, ALT, AST but not 
ALP. RR Pruritus 0.44 (95% CI 0.30-0.66)
*Qin et al., 2000 [69] RCT 110 1000 mg/d iv vs. 
placebo
4 wk RR Pruritus 0.57 (95% CI 0.39-0.83)
⁄Included in systematic review [70].
RCT, randomised controlled trial.
Reviewshowed that signiﬁcantly more SAMe-treated patients reported a
>50% increase in general well-being (SAMe 84% vs. placebo 29%,
p <0.01) [67]. These ﬁndings were supported by a subsequent
Italian study. Here, 640 IHC patients were allocated to one of
two different parenteral dosing schedules (500 mg/day im or
800 mg/day iv) for 15 days in a non-randomised, non-placebo
controlled, observational study [66]. The majority of patients
recruited had chronic viral hepatitis with or without concomitant
excess alcohol consumption and approximately 60% were cir-
rhotic at enrolment. Little additional information as to whether
patients were inpatients or outpatients at the time of the study
was provided. Over two-thirds of participants reported substan-
tial improvements in subjective symptoms of pruritus and fatigue
using a visual analogue scale and reductions in serum markers of
cholestasis were also observed [66]. Neither parenteral regimen
was found to be superior to the other. Although these studies
provide supportive evidence for the use of SAMe in chronic liver
disease, the study cohorts were poorly deﬁned and methodology
was not to current standards for clinical trials. This is particularly
so for the latter study, which was not randomised and had no
control arm, making it difﬁcult to conﬁdently draw conclusions
that inﬂuence practice. Importantly, neither study addressed
duration of effect or whether this translated into any tangible
prognostic beneﬁt.
There have been several smaller studies that have also exam-
ined symptom severity (fatigue and/or pruritus) as an end point
[67–69]. The value of SAMe as a treatment for pruritus was
addressed by the Agency for Healthcare Research and Quality in
2002 (http://archive.ahrq.gov/clinic/tp/sametp.htm) [70]. In a
meta-analysis of four smaller, heterogeneous studies addressing
IHC of mixed aetiology unrelated to pregnancy (Table 1), the
authors concluded that SAMe therapy was superior to placebo,
signiﬁcantly reducing pruritus (relative risk 0.45, 95% CI 0.37–
0.55) and serum bilirubin levels (pooled estimate, p = 0.02) how-
ever, there was insufﬁcient evidence to compare efﬁcacy with
other agents such as ursodeoxycholic acid [70].
Pre-clinical and clinical therapeutic evidence in cholestasis of
pregnancy
Cholestasis of pregnancy is associated with a high risk of adverse
perinatal outcomes, including preterm birth (19–60%), meconium
passage (27%), foetal distress (22–41%), and foetal death (0.4–
4.1%) [71]. Risk increases with fasting serum bile acid levels
>40 lmol/L [71]. The use of SAMe to relieve symptoms and lower
bile salt levels in this condition has been studied by several
groups. The largest study randomised 78 patients with cholesta-
sis of pregnancy at <36 weeks gestation to SAMe, ursodeoxychol-
ic acid (UDCA) or combination therapy until delivery. Both1102 Journal of Hepatology 2012therapies were equally effective at improving pruritus, however,
women receiving UDCA had a signiﬁcantly greater improvement
in the concentration of serum bile acids (p = 0.001) and clinical
biochemistry than those receiving SAMe [72]. A systematic
review by members of the Cochrane Collaboration (performed
in 2001 and updated 2010) identiﬁed ﬁve randomised control tri-
als that met their inclusion criteria (these and others are listed in
Table 2), however, analysis was hampered by their heterogeneity
and several methodological problems were identiﬁed in the stud-
ies [73]. The drug was generally well tolerated in all studies with
no serious adverse events reported, however, the authors con-
cluded that there was insufﬁcient evidence to support the use
of SAMe or UDCA in cholestasis of pregnancy [73].
Alcoholic liver disease
Internationally, alcoholic liver disease (ALD) poses a major bur-
den on healthcare resources. Excess alcohol consumption (typi-
cally a threshold of >20 g/day for women and >30 g/day for
men is adopted) is associated with progressive liver injury rang-
ing from steatosis, through alcoholic steatohepatitis to cirrhosis.
Pathogenesis is driven by a combination of direct hepatotoxic
effects of alcohol; ROS generation by cytochrome P450 (CYP2E1);
bacterial translocation from the gut promoting LPS-induced
Kupffer cell TNFa and pro-inﬂammatory cytokine release; and
innate immune system activation (recently reviewed elsewhere
[74]). In addition, patients with ALD frequently exhibit multiple
nutritional deﬁciencies including protein energy malnutrition
and thiamine (vitamin B1), vitamin B6, vitamin B12, and folate
deﬁciency [75]. The reasons for these deﬁciencies are multifacto-
rial and include poor diet, intestinal malabsorption, and reduced
hepatic uptake [75]. Additionally, speciﬁc chemical interactions
also interfere with normal physiological processes, for example,
the ethanol metabolite acetaldehyde displaces the active form
of vitamin B6 (pyridoxal phosphatase) from its hepatic binding
site [76]. As discussed above, these nutrients are essential for
normal methionine metabolism and so deﬁciency will have
important deleterious effects, impairing remethylation of homo-
cysteine by MS and BHMT and its metabolism to form glutathi-
one, thereby degrading defenses against oxidative stress. The
consequent increase in hepatocellular homocysteine will alter
the catalytic equilibrium of the reversible enzyme SAH hydrolase,
altering the SAH:SAMe ratio and inhibiting many SAMe depen-
dent methylation reactions (Fig. 1). Conﬁrming this, liver biopsies
from patients with alcoholic hepatitis demonstrate signiﬁcant
SAMe depletion and 50% reduced expression of MAT1A as well
as the genes encoding MS and CBS [77]. Similar results are found
in patients with both alcoholic and non-alcoholic cirrhosisvol. 57 j 1097–1109
Table 2. Selected clinical trials of SAMe in cholestasis of pregnancy.
Study, [Ref.] Design Subjects (n) SAMe dose (g/day) Duration Outcomes
*Nicastri et al., 1998 [113] RCT 32 women at 30-37 wk 
gestation
800 mg/day po vs. 
UDCA vs. SAMe + 
UDCA vs. placebo
20 d Combination SAMe and UDCA better 
than either alone or placebo for bile salts, 
bilirubin, ALT, ALP, pruritus, neonatal and 
maternal outcome
*Ribalta et al., 1991 [114] RCT 18 women before 32 
wk gestation
800 mg/day iv vs. 
placebo
20 d
ALT, ALP, pruritus, neonatal and maternal 
outcome
*Frezza et al., 1990 [115] RCT 30 women 800 mg/day iv vs. 
placebo
Until 
delivery 
(mean 
18 d)
SAMe improved bile salts, bilirubin, ALT, 
ALP, pruritus, neonatal and maternal 
outcome
*Frezza et al., 1984 [116] RCT 18 women at 28-32 wk 
gestation
200 mg/day po vs. 
800 mg/day po vs. 
placebo
Until 
delivery
SAMe 800 mg/day improved clinical bio-
chemistry, pruritus, neonatal and maternal 
outcome
*Floreani et al., 1996 [117] RCT 20 women before week 
34 gestation
1 g/day im vs. 
UDCA
>15 d SAMe had no effect on bile salts, bilirubin, 
ALT, ALP, pruritus, neonatal and maternal 
outcome 
Lafuenti et al., 1988 [118] Open 
label
17 patients 1800 mg/day po 
and 600 mg/day po
n.a. Manuscript out of print
Catalino et al., 1992 [119] Open 
label
55 patients, 
no comparator
800 mg/day iv 10-30 d Improved bile salts, bilirubin, ALT, ALP, 
pruritus vs. baseline
Roncaglia et al., 2004 [72] RCT 46 patients, before 36 
wk gestation
SAMe 1 g/day po 
vs. UDCA 600 mg/
day 
until 
delivery
UDCA was more effective than SAMe in 
lowering bile acid levels. Both improved 
pruritus 
No benefit of SAMe for bile salts, bilirubin,
⁄Included in Cochrane systematic review [73].
RCT, randomised controlled trial; n.a., not available.
JOURNAL OF HEPATOLOGY[26,78] where MAT activity was suppressed, and in a range of ani-
mal models of alcoholic liver injury including mice [42], rats
[44,79], baboons [80], and micropigs [81,82].
Pre-clinical and clinical therapeutic evidence
The effects of SAMe supplementation in ALD have been explored
in a number of animal models and in several clinical trials. In gen-
eral, the results of pre-clinical studies have been positive
although this may be inﬂuenced by publication bias. In isolated
perfused rat liver, SAMe attenuated ethanol toxicity by restoring
mitochondrial and total liver glutathione [83]. SAMe supplemen-
tation has been shown to reverse SAMe and glutathione depletion
in ethanol fed baboons [80] and rats [43]; reduce hepatic ﬁbro-
genesis following carbon-tetrachloride exposure in rats [84]
(although as noted earlier, not following bile duct ligation
[41,64,65]); restore hepatocyte mitochondrial inner-membrane
ﬂuidity in ethanol fed rats [45]; normalise mitochondrial gluta-
thione handling in ethanol fed rats [45]; and prevent TNFa-med-
iated glutathione depletion, ameliorate steatosis, hepatocyte
necrosis, and ALT elevations in ethanol fed mice [42].
Encouraged by these data, several groups have conducted
clinical trials examining the efﬁcacy of SAMe therapy across a
range of different end points in patients with ALD. Many were
small, observational studies with signiﬁcant design ﬂaws and
have only been published in abstract form. Selected trials are
summarized in Table 3. The largest of these was a 2-year Spanish
multi-center study examining the effect of oral SAMe in 123
patients with cirrhosis due to alcoholic liver disease [85]. 62
patients (53 male, 9 female) were randomised to SAMe 1.2 g/
day and 61 patients (53 male, 8 female) placebo. Of note, approx-
imately a quarter of the patients also had chronic viral hepatitis
[86]. Outcomes studied were all-cause mortality, liver transplan-
tation, complications of liver disease, and clinical biochemistry.Journal of Hepatology 2012This study found that a combined all-cause mortality/transplan-
tation end point fell from 30% in the placebo arm to 16% in those
treated with SAMe, however, the effect did not reach statistical
signiﬁcance (p = 0.077) unless those with more advanced disease
(Child score C) were excluded from the analysis, 29% vs. 12%
(p = 0.025) [85]. No signiﬁcant difference between arms in the
number of patients that experienced severe complications of cir-
rhosis was observed during the study.
An update of the 2001 systematic review by members of the
Cochrane Collaboration identiﬁed nine randomised control trials
that met their inclusion criteria (Table 3) [86]. These studies,
including the trial discussed above, which was the only study
considered to have used adequate methodology, recruited a total
of 434 patients. No signiﬁcant effect of SAMe on all cause mortal-
ity (relative risk (RR) 0.62, 95% conﬁdence interval (CI) 0.30–
1.26); liver-related mortality (RR 0.68, 95% CI 0.31–1.48); com-
bined all-cause mortality or transplantation RR 0.55, 95% CI
0.27–1.09); or liver-related complications (RR 1.35, 95% CI
0.84–2.16) was identiﬁed [86]. The authors concluded that the
available evidence was insufﬁcient to either support or refute
the beneﬁt of SAMe therapy in ALD and that, to address this,
there was a need for a large, well conducted, placebo-controlled,
randomised clinical trial that stratiﬁed patients not only by alco-
hol consumption but also by presence of co-existent diseases
such as chronic viral hepatitis.
A recent North American study, published since the Cochrane
analysis was completed, randomised 37 abstinent ALD patients to
1.2 g/day SAMe or placebo for 6 months. Eleven patients were
excluded from the ﬁnal analysis due to on-going alcohol con-
sumption but 14 of the remaining patients had undergone paired
liver biopsies at the start and end of the study. Fasting serum
SAMe levels were found to have increased during the course of
the study in the SAMe treatment group. The entire cohort showedvol. 57 j 1097–1109 1103
Table 3. Selected clinical trials of SAMe in ALD.
Study, [Ref.] Design Subjects (n) SAMe dose (g/d) Duration Outcomes
*Altomare et al., 1988 
[120]
RCT 18 inpatients with 
severe decompensated 
ALD; 17 outpatients 
with ALD
1.2 g/d po vs. 
placebo
4 wk or 
6 mo glutathione, cysteine, taurine and 
reduced methionine 
*†Chawla et al., 1999 [121] RCT 7 patients with stable 
ALD cirrhosis
800 mg/d iv vs. 
placebo
17 d Improved clinical biochemistry and 
hepatic methionine handling
*Cibin et al., 1988 [122] RCT 64 patients with alco-
hol dependence but 
not cirrhosis
200 mg/d im vs. 
placebo
30 d Reduced anxiety, depression, gGT and 
alcohol consumption
*†Corrales et al., 1991 
[123]
RCT 16 patients with ALD 1.2 g/d po vs. 
placebo
4 wk Improved hepatic methionine handling 
*Diaz Belmont et al., 1996 
[124]
RCT 45 alcoholic hepatitis 
patients
200 mg/d iv vs. 
placebo
15 d Increased plasma glutathione
*Loguercio et al., 1994 
[125]
RCT 40 (20 non-cirrhotic, 20 
cirrhotic)
2 g/d iv vs. placebo 15 d Increased RBC glutathione and cysteine 
concentrations
*Mato et al., 1999 [85] RCT 123 patients with ALD 
cirrhosis
1.2 g/d po vs. 
placebo
24 mo SAMe improved survival and reduced 
liver transplantation in Child-Pugh A/B 
patients 
*†Trespi et al., 1997 [126] RCT 210 patients with ALD SAMe 1.5 g/d plus 
ursodeoxycholic/
tauroursodeoxychol-
ic acid vs. ursode-
oxycholic/taurourso-
deoxycholic alone
24 wk Greatest clinical biochemistry improve-
ment with SAMe plus tauroursodeoxy-
cholic acid 
*Vendemiale et al., 1989 
[46]
RCT 39 patients with ALD No treatment vs. 
SAMe 1.2 g/day vs. 
placebo
24 wk
glutathione 
Medici et al., 2011 [87] RCT 37 (14 with biopsies 
pre and post-treat-
ment)
1.2 g/d vs. placebo 24 wk No improvement in clinical, biochemical 
or histological disease 
#Fiorelli et al.,1999 [66] NR, open 
label
640 IHC patients (18% 
ALD)
800 mg/d iv or 500 
mg/d im
15 d Clinical biochemistry and symptomatic 
improvement
Significantly increased hepatic
SAMe significantly increases total
⁄Included in Cochrane systematic review [86].
#Mixed chronic liver disease including ALD.
Published only as abstract.
RCT, randomised controlled trial; NR, non-randomised.
Reviewan overall improvement of AST, ALT, and bilirubin levels after
24 weeks, most probably due to abstinence from alcohol, but
no differences between the treatment groups in any clinical, bio-
chemical or histological parameters (steatosis, inﬂammation,
ﬁbrosis, and Mallory–Denk hyaline bodies) were identiﬁed [87].
Although this study is relatively small and arguably 6-month fol-
low-up is too little time for substantial histological changes in
ﬁbrosis to occur, the methodology used was sound. The results
led the authors to conclude that ‘SAMe was no more effective
than placebo’ in the treatment of ALD [75,87]. It is interesting
to note that, one previous study has also performed biopsies
pre- and post-6 months of SAMe therapy [46]. However, the
authors did not present any histological data (despite stating in
the methods section that tissue underwent histopathological
assessment), only showing data that demonstrated SAMe
increased intra-hepatic glutathione and improved clinical bio-
chemistry [46].
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD), represents a spectrum
encompassing steatosis, non-alcoholic steatohepatitis (NASH)
and cirrhosis in the absence of alcohol abuse and has been1104 Journal of Hepatology 2012recognised as the most common cause of liver dysfunction in
the majority of developed countries [6]. NAFLD is strongly asso-
ciated with obesity, insulin resistance or type 2 diabetes melli-
tus and dyslipidaemia and so may be considered the hepatic
manifestation of the metabolic syndrome [88–90]. Perhaps
unsurprisingly, given the gross histological similarities between
ALD and NAFLD, there is now increasing evidence to suggest
that both conditions share common pathogenic processes [91].
The initiating events in NAFLD are founded on the development
of obesity and insulin resistance and increased hepatic free fatty
acid (FFA) ﬂux. This imbalance between the rate of import/syn-
thesis and the rate of export/catabolism of fatty acids leads to
development of steatosis, which represents an adaptive
response through which potentially lipotoxic FFAs are parti-
tioned into relatively stable triglyceride stores [92]. When these
are overwhelmed, steatohepatitis develops due to the increased
oxidative stress produced during b- and x-fatty acid oxidation;
direct lipotoxicity; endotoxin/TLR4 induced activation of the
innate immune system causing cytokine release; and endoplas-
mic reticulum (ER) stress. Consequent cellular damage triggers a
mixture of immune mediated hepatocellular injury and both
necrotic and apoptotic cell death pathways culminating in hepa-
tic ﬁbrosis [3,93–95].vol. 57 j 1097–1109
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Pre-clinical and clinical therapeutic evidence
SAMe may inﬂuence the pathogenesis of NAFLD both through its
role as a precursor for glutathione synthesis and also as a methyl
donor in the synthesis of phosphatidylcholine, which is required
for VLDL assembly and hepatic triglyceride export. Evidence of a
role for methionine metabolism and SAMe in the pathogenesis of
NAFLD has largely been based on the study of pre-clinical models.
Prolonged consumption of a methionine-choline deﬁcient (MCD)
diet is associated with hepatic SAMe depletion and development
of a histological ﬁbrosing steatohepatitis in rodents [29,96]. Simi-
lar changes are observed in MATO mice that, as discussed earlier,
lackMat1a and so are unable to synthesize SAMe [28,29]. Investi-
gation of the mechanisms underlying these observations demon-
strates that, even before NAFLD is histologically apparent, there
is a potent effect of Mat1a deletion on lipid handling [97]. Three-
month old MATO mice exhibited decreased mobilization of TG
stores, TG secretion in VLDL, and phosphatidylcholine synthesis
via phosphatidylethanolamine N-methyltransferase. In addition,
the authors report that administration of SAMe for 7 days was suf-
ﬁcient to rectify the deﬁcits in VLDL assembly and features of the
secreted lipoproteins [97]. They conclude that Mat1a is required
for normal VLDL assembly and plasma lipid homeostasis in mice
and that impaired VLDL synthesis, mainly due to SAMe deﬁciency,
contributes to NAFLD development in MATO mice [97]. A recent
human study has attempted to determine the extent to which
methionine metabolism and SAMe contribute to the pathogenesis
of NASH in man [98]. Studying a cohort of 15 patients with biopsy
provenNASHand19healthy controls, the authors determined that
the rates of remethylation of homocysteine and transmethylation
of methionine (Fig. 1) were signiﬁcantly reduced in NASH and
hypothesised that this may in part be due to inactivation of
MATI/III by increased oxidative stress [98].
No pharmacological agents are currently licenced speciﬁcally
for NASH therapy and as yet there have been no clinical studies
that address the utility of SAMe in this condition [99]. Several
studies have, however, reported encouraging results with the
use of the anti-oxidant vitamin E [100,101] and so it may be that
the anti-oxidant effects of SAMe via augmenting hepatic glutathi-
one synthesis could provide clinical beneﬁt. The methyl donor
betaine (trimethylglycine) is required for BMHT-mediated reme-
thylation of homocysteine to methionine and has been shown to
reduce hepatic SAH and increase SAMe in animal models (Fig. 1)
[11]. Betaine has been tested as a therapy for NASH in two clinical
trials, an initial pilot study that yielded positive results and a sub-
sequent large randomised placebo-control trial, which did not
[102,103]. This second study randomised 55 patients with biopsy
proven NASH to betaine (20 g/day) or placebo for 1 year. The
analysis demonstrated that betaine therapy effectively increased
serum methionine and SAMe levels but did not signiﬁcantly
reduce SAH or ameliorate histological steatohepatitis [103]. It
would seem timely to formally assess the efﬁcacy of direct SAMe
supplementation in NAFLD.
Viral hepatitis
Several of the studies so far discussed have included in the
cohorts a signiﬁcant number of patients with viral hepatitis and
have indicated that SAMe may be effective in IHC of viral aetiol-
ogy. An effect supported in a viral hepatitis cohort by an open-
label study comparing SAMe and traditional Chinese remedies
for the treatment of jaundice [104]. Arguably of greater interest,Journal of Hepatology 2012however, are recent studies demonstrating that SAMe may be an
effective adjunctive therapy in the treatment of chronic hepatitis
C (HCV).
Pre-clinical and clinical therapeutic evidence
Despite recent advances in our understanding of genetic modiﬁ-
ers of host response to Pegylated IFNa/Ribavarin based anti-viral
regimens [105–107], the mechanisms that determine response
remain incompletely understood. One mechanism appears to be
HCV-induced viral interference with IFNa signal transduction
and Jak-STAT signalling due to STAT1 hypomethylation, facilitat-
ing binding of its inhibitor, protein inhibitor of activated STAT1
(PIAS1). [108]. This effect is reversed in vitro by SAMe and betaine
which restore STAT1 methylation, improve IFNa signalling and
enhance the antiviral effect of IFNa in cell culture [109]. These
effects have also been described in vivo. In an open-label pilot
study of combined SAMe (1200 mg/day) and betaine (6 g/day)
treatment in HCV previous non-responders, there was no evi-
dence of any direct anti-viral effect of SAMe, however, SAMe
treatment was associated with an increase in early virological
response but this did not translate into greater sustained virolog-
ical response [110]. A further clinical study in a group of 24 HCV
genotype 1 non-responders found that addition of SAMe was
associated with improved viral kinetics in the second-phase slope
of viral decline (Control 0.11 ± 0.04 log10 IU/ml/wk vs. SAMe
0.27 ± 0.06; p = 0.009) and higher rates of early and sustained
viral clearance [111]. This effect was associated with signiﬁcantly
greater interferon-stimulated gene (ISG) expression in peripheral
blood mononuclear cells (PBMCs) and, once again, SAMe was
shown to increase induction of ISGs and the antiviral effects of
interferon by increasing STAT1 methylation in vitro [111]. Whilst
these effects will need to be replicated in large randomised-con-
trolled trails, the authors conclude that SAMe represents the ﬁrst
interferon sensitising agent with in vivo efﬁcacy and that it may
be a useful adjunct to interferon-based therapy [111].
A study examining the carcinogenic effects of hepatitis B
(HBV) showed that the hepatocellular cytoplasmic level of HBV
X protein (HBx) was strongly correlated with MAT2A expression
in HCC samples [112]. In vitro, HBx was shown to reduce MAT1A
gene expression and SAMe production whilst directly activating
MAT2A expression in a dose-dependent manner through binding
of NF-jB and CREB to theMAT2A gene promoter. In addition, HBx
and/or overexpression of MAT2A were able to inhibit apoptosis in
HCC cells [112]. Although this has not been formally examined,
these data offer a biological rationale for the use of SAMe to pre-
vent HCC in HBV. Clinical trials to validate this are, however,
required.Conclusions and future directions
In conclusion, there is strong pre-clinical evidence that SAMe
has important physiological roles in health and that liver dis-
ease of various aetiologies may perturb these. Furthermore, it
is apparent that hepatocellular SAMe concentration can inﬂu-
ence diverse pathophysiological processes including tissue oxi-
dative stress, mitochondrial function, hepatocellular apoptosis,
and malignant transformation, not to mention the intriguing
data suggesting that chronic viral hepatitis may modulate
interferon sensitivity through SAMe. These data suggest that
SAMe could offer substantial clinical beneﬁts, however, veryvol. 57 j 1097–1109 1105
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few large, high-quality clinical trials have been performed to
prove or refute this. The challenge is now to address this evi-
dence deﬁcit. We suggest that, rather than examining abstract
features of IHC, future clinical studies should be conducted in
deﬁned, well-characterised patient groups and should be
focussed on the effects of SAMe on clinically relevant ‘hard
end points’, possibly in three key areas where there is a good
pre-clinical rationale for efﬁcacy:
 The role of SAMe, alone or in combination with vitamin B6/
B12 and folate supplementation [75], in the treatment of
inﬂammation in NASH;
 The utility of SAMe as an adjunct to pegylated IFNa/Ribavarin
based anti-viral therapy in chronic HCV infection. This would
be of particular interest in HCV genotype 4 patients which
have low sustained viral response rates with standard therapy
and are currently under-represented in trials of novel protease
inhibitors;
 The value of SAMe as prophylaxis to reduce the incidence of
HCC in chronic liver disease (e.g. HBV).
It is hoped that, by addressing these, the therapeutic potential
of SAMe can be translated from bench to the bedside.Conﬂict of interest
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• S-Adenosyl-L-methionine (SAMe; AdoMet) is a 
metabolically pleiotropic molecule that is the precursor 
for the synthesis of the anti-oxidant glutathione and is 
also an important methyl donor
• 
diverse pathophysiological processes including tissue 
oxidative stress, mitochondrial function, hepatocellular 
apoptosis and malignant transformation 
• SAMe synthesis is depressed in chronic liver disease. 
Pre-clinical studies indicate this could exacerbate liver 
injury and so supplementation may be a useful therapy 
• SAMe has been widely adopted in Eastern Europe, 
Russia, China, Southern Asia and South America as 
a therapy for chronic liver disease and intra-hepatic 
cholestasis
• To date no large, high-quality, randomised placebo-
controlled clinical trials have been performed that 
states. Further clinical studies in well-characterised, 
should be focussed on measuring the effects of SAMe 
supplementation on clinically relevant ‘hard end-points’ 
definitively establish clinical utility in specific disease
disease-specific patient groups are needed and
Hepatocellular SAMe concentration can influence
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